L-Ornithine + L-Aspartate 5mg/10ml Injection is a sterile liquid injection that contains L- ornithine & L-aspartate which are used as active ingredients. The formulation of dual amino acid contains an optimized range of concentration, solution uniformity, pH, clarity, sterility, container-closure integrity. As this formulation is offered as a sterile formulation so formulation manufacturing environments and microbiological controls are important. This formulation may be integrated into a variety of injectable products for pharmaceutical firms wishing to broaden their range of injectable items in a PCD pharma franchise.
Development of the formulation The goal for formulation development was an aqueous injectable formulation that would deliver L-ornithine and L-aspartate in a stable, uniform solution. Starting with the raw materials is critical, as the purity, physical appearance and moisture content will affect the end- formulation.
The amino-acid components are added in a defined order during the manufacturing process. Solubility of the two components and their interaction with the formulation environment are taken into account when determining the composition and processing parameters.
PH is a significant development parameter for the injectable solution and is within the defined product specification. The preparation should have uniform appearance with no visible precipitates, crystallisation or formation of particulate.
When necessary, the excipients are determined after compatibility evaluation with active substances and selected primary containers.
Whilst a defined 10ml presentation it contains two actives, the correct weighed and solution preparation for each raw materials are critical. Each raw material is checked against the approved specification prior to use in manufacture.
The article must be mixed with the appropriate vehicle, manufactured under specified manufacturing conditions and then where possible sequentially added thereafter. Agitation, processing time, temperature and bulk hold conditions are set at process development.
The bulk solution is examined for homogeneity and physical characteristics prior to the sterile filling step. Sterile filtration can, where relevant to the end manufacturing process, be carried out with a suitable qualified filtration unit.
Essential elements of the sterile manufacturing system include environmental monitoring, equipment sanitization, personnel procedures and procedures for the controlled area. These control measures support the microbiological quality of the injectable product in bulk and as a finished product.
The quality control of L-Ornithine + L-Aspartate Injection is comprised of chemical, physical and microbiological examinations. The individual amino-acid constituents are identified and measured, which establish their presence and stipulated amount.
Finished-product testing shall include, as appropriate, the following, e.g. pH, clarity, colour, fill volume, visible particulate matter, sub-visible particulate matter, sterility, bacterial endotoxins, and other tests that are part of the approved specification for the product.
The analytical procedure should be able to separate and quantify the two active ingredients in the presence of each other. Appropriate methods of analysis are those that are able to quantitate the active ingredients in the final formulation for the intended use.
During the individual bottle assessment, visual inspection of each container is useful to detect other irregularities in colour, particles, precipitation, container damage, or any other visible inconsistencies. However, each batch is released following the specifications.
Fill stage involves filling the correct volume of liquid formulation into the appropriate sterile primary containers. It also requires fill-volume control to ensure uniformity of unit doses and provide the correct presentation of product.
Your formulation will be packed in amps, vials or other injectable containers after the pack design has been approved. The material of the container should be compatible with the aqueous amino-acid formulation and should not negatively influence the quality of the formulation throughout the pack shelf life.
Container-closure integrity is relevant as the integrity of the packaging system has to be maintained at the desired sterility throughout the product life cycle. Seal integrity, leakage and dimensional compatibility, as well as closure performance can be tested as part of the packaging development.
Once filled and sealed, units may be inspected and manipulated by secondary packaging of the mixed units as part of the normal manufacturing process.
Stability testing is carried out to establish the stability of L-Ornithine + L-Aspartate 5mg/10ml Injection to the designated quality characteristics of the product throughout its proposed shelf life. Samples are tested at pre-determined time intervals.
The stability requirements, within the limits specified for each specification, are as follows: assay of each active; pH; colour; appearance; visible particulate matter; parameters relating to sterility; and performance of the container-closure system.
The primary packaging system is part of the stability programme as the formulation/container interaction has the potential to affect the quality of the product over time. When preparing the final pack configuration appropriate safeguards from unsuitable storage conditions are taken into consideration.
Storage and shelf-life conditions should be established in accordance with documented stability data and regulatory requirements.
L-Ornithine + L-Aspartate 5mg/10ml Injection is a sterile preparation which is technically a controlled preparation with a simultaneous control of dual-active concentration, uniformity of the solution, pH, sterility assurance, control of particulate matter and the integrity of container.
If you are a PCD Pharma Franchise company with a diversified range of PCD Pharma Franchise and other products, you may integrate this injectable into a professionally managed collection of Pharmaceuticals backed by specified raw material requirements, controlled sterile manufacturing, verified or qualified analytical methods, and packaging.
Starting from raw-material inspection and processing, preparartion of bulk solutions to sterile filteration (if needed), aseptic filling, testing of final products, stability testing, and finally packaging - all processes should result in consistent quality of products. The manufacturing process is designed systematically so that the composition and physical attributes of the injection remain constant in every batch of production.
L-Ornithine + L-Aspartate 5mg/10ml Injection with formulation, sterile manufacturing, quality control, stability and packaging details.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech